Safi Bahcall, Synta Pharmaceuticals
S
Safi Bahcall
CEO, Synta Pharmaceuticals
FORMER PROFESSION: Astrophysicist (like both his parents)
GOAL: For Synta to be the next Celgene or Genentech
Until 2003, everything was abstract. Papers, ideas, concepts, and theories. And then I went to Boston to meet the first patient who was getting dosed with our first drug for the first time. The patient was a young guy, with an IV bag going into his arm, who had cancer. It was our drug in that bag, and he was looking at me, hoping that our drug would make him not die. The doctor and nurse just left, so I sat down in the chair next to his bed, and we started talking—about travelling, restaurants, biking. And all the stuff that I've done—the stock options, business plans, whatever—they all just melted way. Everything in the past just faded. And I realized that everything that counted, it was there. It's those moments that reframe everything and let you realize how important it is to do what we are doing."
Safi Bahcall
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
